Head And Neck Cancer Therapeutics Market Size, Share & Trends Analysis Report By Therapy Type (Chemotherapy, Immunotherapy, Targeted Therapy), By Route Of Administration, By Distribution Channel, By Region, And Segment Forecasts, 2022 - 2030
This report can be delivered to the clients within 3 Business Days
Head And Neck Cancer Therapeutics Market Growth & Trends
The global head and neck cancer therapeutics market size is expected to reach USD 3.5 billion by 2030, according to a new report by Grand View Research, Inc. The market is expected to expand at a CAGR of 12.5% from 2022 to 2030. Increasing advancements in the diagnosis and treatment of head and neck cancer (HNC) are anticipated to propel market growth, as they are cost-effective and more specific to target over surgeries. The increasing prevalence of different types of HNCs and the growing geriatric population are major drivers of the market.
According to the Cancer Research Institute, in 2021, approximately 54,000 people were diagnosed with different types of HNC and about 11,000 deaths were reported in the U.S. Heavy alcohol consumption, prolonged sun exposure, cancer-causing viral infection such as Epstein-Barr virus (EBV) and tobacco consumption are some of the major factors contribute to rising incidence of various head and neck cancers worldwide.
Furthermore, according to the United Nations, it was estimated that, in 2020, there were around 727 million people aged 60 years and above worldwide. In addition, the geriatric population is expected to increase from 9.3% in 2020 to 16% in 2050. Aging weakens the immune system and makes people susceptible to different types HNCs, consequently, increasing the demand for therapeutic drugs for the treatment of disease.
Moreover, an increase in R&D activities for the development of novel targeted drugs and a multidisciplinary therapeutic approach is expected to lead to an increased survival rate of patients suffering from head and neck cancers. For instance, Merck/Debiopharm’s Xevinapant is currently in phase III clinical trials for the treatment of squamous head and neck cancer. It has received breakthrough therapy designation from the U.S. FDA.
Supportive reimbursement policies are also expected to drive market growth. Several organizations provide financial assistance to patients and their caregivers for purchasing medicines. For instance, in July 2022, British Colombia Cancer included Capecitabine, Carboplatin, Cetuximab, Cisplatin, Docetaxel, Doxorubicin, Fluorouracil, and Leucovorin Calcium in their benefit drug list. Drugs included in this list are applicable for reimbursement for approved indications.
Head And Neck Cancer Therapeutics Market Report Highlights
Head And Neck Cancer Therapeutics Market Growth & Trends
The global head and neck cancer therapeutics market size is expected to reach USD 3.5 billion by 2030, according to a new report by Grand View Research, Inc. The market is expected to expand at a CAGR of 12.5% from 2022 to 2030. Increasing advancements in the diagnosis and treatment of head and neck cancer (HNC) are anticipated to propel market growth, as they are cost-effective and more specific to target over surgeries. The increasing prevalence of different types of HNCs and the growing geriatric population are major drivers of the market.
According to the Cancer Research Institute, in 2021, approximately 54,000 people were diagnosed with different types of HNC and about 11,000 deaths were reported in the U.S. Heavy alcohol consumption, prolonged sun exposure, cancer-causing viral infection such as Epstein-Barr virus (EBV) and tobacco consumption are some of the major factors contribute to rising incidence of various head and neck cancers worldwide.
Furthermore, according to the United Nations, it was estimated that, in 2020, there were around 727 million people aged 60 years and above worldwide. In addition, the geriatric population is expected to increase from 9.3% in 2020 to 16% in 2050. Aging weakens the immune system and makes people susceptible to different types HNCs, consequently, increasing the demand for therapeutic drugs for the treatment of disease.
Moreover, an increase in R&D activities for the development of novel targeted drugs and a multidisciplinary therapeutic approach is expected to lead to an increased survival rate of patients suffering from head and neck cancers. For instance, Merck/Debiopharm’s Xevinapant is currently in phase III clinical trials for the treatment of squamous head and neck cancer. It has received breakthrough therapy designation from the U.S. FDA.
Supportive reimbursement policies are also expected to drive market growth. Several organizations provide financial assistance to patients and their caregivers for purchasing medicines. For instance, in July 2022, British Colombia Cancer included Capecitabine, Carboplatin, Cetuximab, Cisplatin, Docetaxel, Doxorubicin, Fluorouracil, and Leucovorin Calcium in their benefit drug list. Drugs included in this list are applicable for reimbursement for approved indications.
Head And Neck Cancer Therapeutics Market Report Highlights
- By therapy type, the immunotherapy segment held the largest market share in 2021 due to the presence of supportive reimbursement policies and the higher efficacy of immunotherapy drugs as an effective treatment for head and neck cancer diseases
- By route of administration, the oral segment is expected to be the fastest-growing segment during the forecast period. This can be attributed to the high safety, efficacy, and tolerability associated with this route of administration among rare disease patients
- By distribution channel, the retail and specialty pharmacy segment dominated the market in 2021. This dominance can be attributed to the preference of oncologists for specialty pharmacies. Oncologists often need specialty pharmacies so that with extensive therapeutic knowledge, they can support treatment plans and relieve them from the administrative burden
- Asia Pacific is expected to be the fastest-growing region during the forecast period. The growth of the region can be attributed to the entry of new products into the region. For instance, in 2020, NMPA approved ERBITUX (Cetuximab) developed by Merck and Co., Inc., to treat patients with head and neck cancer in China
CHAPTER 1 METHODOLOGY AND SCOPE
1.1 Market Segmentation
1.1.1 Segment scope
1.1.2 Regional scope
1.1.3 Estimates and Forecast Timeline
1.2 Research Methodology
1.3 Information Procurement
1.3.1 Purchased Database
1.3.2 GVR’s Internal Database
1.3.3 Secondary Sources
1.3.4 Primary Research
1.3.5 Details of Primary Research
1.4 Information or Data Analysis
1.4.1 Data Analysis Models
1.5 Market Formulation & Validation
1.6 Model Details
1.6.1 Commodity Flow Analysis
1.6.1.1 Approach 1: Commodity flow approach
1.6.1.2 Approach 2: Country wise market estimation using bottom up approach
1.6.1.3 Approach 3: Country wise market estimation using top down approach
1.7 Global Market: CAGR Calculation
1.8 Research Assumptions
1.9 Key KoL Responses
1.10 Market Share Calculations
1.11 List of Secondary Sources
1.12 Objectives
1.12.1 Objective 1:
1.12.2 Objective 2:
1.13 List of Abbreviations
CHAPTER 2 EXECUTIVE SUMMARY
2.1 Market Summary
CHAPTER 3 HEAD AND NECK CANCER THERAPEUTICS MARKET - INDUSTRY OUTLOOK
3.1 Market Lineage Outlook
3.1.1 Parent Market Lineage Outlook
3.1.2 Related/Ancillary Market Outlook
3.2 Penetration & Growth Prospect Mapping
3.3 Market Dynamics
3.3.1 Market Drivers Analysis
3.3.1.1 Increasing prevalence of head and neck cancers
3.3.1.2 Rising geriatric population
3.3.1.3 Increasing R&D and strong presence of pipeline product
3.3.1.4 Supportive reimbursment policies and rising awareness about disease
3.3.2 Market Restraint Analysis
3.3.2.1 Paucity of data related to safety and efficacy
3.3.2.2 High cost of treatments
3.4 Head and Neck Cancer Therapeutics Market Analysis Tools
3.4.2 Industry Analysis - Porter's
3.4.3 SWOT Analysis, By Factor (Political & Legal, Economic and Technological)
3.4.3.1 Political and Legal
3.4.3.2 Economic & Social
3.4.3.3 Technological
3.5 Reimbursement & Regulatory Scenario
3.5.1 North America
3.5.1 Europe
3.5.2 Asia Pacific
3.5.3 Latin America
3.5.4 MEA
3.6 Major Deals & Strategic Alliances
3.6.1 New Product Launch
3.6.2 Acquisition
3.6.3 Expansion
3.6.4 Partnerships
3.7 Pipeline analysis
CHAPTER 4 HEAD AND NECK CANCER THERAPEUTICS MARKET ANALYSIS: THERAPY TYPE SCOPE, 2018 - 2030 (REVENUE, USD MILLION)
4.1 Head and Neck Cancer Therapeutics Market: Therapy Type Movement Analysis
4.2 Chemotherapy
4.2.1 Chemotherapy market estimates and forecast, 2018 - 2030 (USD million)
4.3 Immunotherapy
4.3.1 Immunotherapy market estimates and forecast, 2018 - 2030 (USD million)
4.4 Targeted Therapy
4.4.1 Targeted therapy market estimates and forecast, 2018 - 2030 (USD million)
CHAPTER 5 HEAD AND NECK CANCER THERAPEUTICS MARKET ANALYSIS: ROUTE OF ADMINISTRATION SCOPE, 2018 - 2030 (REVENUE, USD MILLION)
5.1 Head and Neck Cancer Therapeutics Market: Route of Administration Movement Analysis
5.2 Injectables
5.2.1 Injectables market estimates and forecast, 2018 - 2030 (USD million)
5.3 Oral
5.3.1 Oral market estimates and forecast, 2018 - 2030 (USD million)
CHAPTER 6 HEAD AND NECK CANCER THERAPEUTICS MARKET ANALYSIS: DISTRIBUTION CHANNEL SCOPE, 2018 - 2030 (REVENUE, USD MILLION)
6.1 Head and Neck Cancer Therapeutics Market: Distribution Channel Movement Analysis
6.2 Retail & Specialty Pharmacies
6.2.1 Retail & specialty pharmacies market estimates and forecast, 2018 - 2030 (USD million)
6.3 Hospital Pharmacies
6.3.1 Hospital pharmacies market estimates and forecast, 2018 - 2030 (USD million)
6.4 Online Pharmacies
6.4.1 Online pharmacies market estimates and forecast, 2018 - 2030 (USD million)
CHAPTER 7 HEAD AND NECK CANCER THERAPEUTICS MARKET ANALYSIS, REGIONAL SCOPE, 2017-2030, (REVENUE, USD MILLION)
7.1 Market Share Analysis by Regional, 2021 & 2030
7.1.1 North America
7.1.1.1 North America market estimates and forecast, 2018 - 2030 (USD Million)
7.1.1.2 U.S.
7.1.1.2.1 U.S. market estimates and forecast, 2018 - 2030 (USD Million)
7.1.1.3 Canada
7.1.1.3.1 Canada market estimates and forecast, 2018 - 2030 (USD Million)
7.1.2 Europe
7.1.2.1 Europe market estimates and forecast, 2018 - 2030 (USD Million)
7.1.2.2 U.K.
7.1.2.2.1 U.K. market estimates and forecast, 2018 - 2030 (USD Million)
7.1.2.3 Germany
7.1.2.3.1 Germany market estimates and forecast, 2018 - 2030 (USD Million)
7.1.2.4 France
7.1.2.4.1 France market estimates and forecast, 2018 - 2030 (USD Million)
7.1.2.5 Italy
7.1.2.5.1 Italy market estimates and forecast, 2018 - 2030 (USD Million)
7.1.2.6 Spain
7.1.2.6.1 Spain market estimates and forecast, 2018 - 2030 (USD Million)
7.1.3 Asia Pacific
7.1.3.1 Asia Pacific market estimates and forecast, 2018 - 2030 (USD Million)
7.1.3.2 Japan
7.1.3.2.1 Japan market estimates and forecast, 2018 - 2030 (USD Million)
7.1.3.3 China
7.1.3.3.1 China market estimates and forecast, 2018 - 2030 (USD Million)
7.1.3.4 India
7.1.3.4.1 India market estimates and forecast, 2018 - 2030 (USD Million)
7.1.3.5 Australia
7.1.3.5.1 Australia market estimates and forecast, 2018 - 2030 (USD Million)
7.1.3.6 South Korea
7.1.3.6.1 South Korea market estimates and forecast, 2018 - 2030 (USD Million)
7.1.4 Latin America
7.1.4.1 Latin America market estimates and forecast, 2018 - 2030 (USD Million)
7.1.4.2 Brazil
7.1.4.2.1 Brazil market estimates and forecast, 2018 - 2030 (USD Million)
7.1.3.3 Mexico
7.1.3.3.1 Mexico market estimates and forecast, 2018 - 2030 (USD Million)
7.1.3.4 Argentina
7.1.3.4.1 Argentina market estimates and forecast, 2018 - 2030 (USD Million)
7.1.5 Middle East and Africa (MEA)
7.1.8.1 Middle East & Africa market estimates and forecast, 2018 - 2030 (USD Million)
7.1.8.2 South Africa
7.1.8.2.1 South Africa market estimates and forecast, 2018 - 2030 (USD Million)
7.1.3.3 Saudi Arabia
7.1.3.3.1 Saudi Arabia market estimates and forecast, 2018 - 2030 (USD Million)
7.1.3.4 South Africa
7.1.3.4.1 South Africa market estimates and forecast, 2018 - 2030 (USD Million)
CHAPTER 8 HEAD AND NECK CANCER THERAPEUTICS MARKET: COMPETITIVE ANALYSIS
8.1 Recent Developments and Impact Analysis, by Key Market Participants
8.1.1 Ansoff matrix`
8.2 Company Categorization
8.2.1 Innovators
8.2.2.1 Market Differentiators
8.3 Vendor Landscape
8.3.1 List of Key Distributors And Channel Partners
8.3.2 Key Customers
8.3.3 Key Company Market Share Analysis, 2020
8.4 Public Companies
8.4.1 Comapany Market Position analysis
8.4.2 Competitive dashboard analysis
8.5 Private Companies
8.5.1 List of Key Emerging Companies
8.6 Regional Network Map
8.8 Company Profiles
8.8.1 Eli Lilly and Company
8.8.1.1 Company overview
8.8.1.2 Financial performance
8.8.1.3 Product benchmarking
8.8.1.4 Strategic initiatives
8.8.2 Sanofi
8.8.2.1 Company overview
8.8.2.2 Financial performance
8.8.2.3 Product benchmarking
8.8.2.4 Strategic initiatives
8.8.3 Merck & Co., Inc.
8.8.3.1 Company overview
8.8.3.2 Financial performance
8.8.3.3 Product benchmarking
8.8.3.4 Strategic initiatives
8.8.4 Clingen Group plc.
8.8.4.1 Company overview
8.8.4.2 Financial performance
8.8.4.3 Product benchmarking
8.8.4.4 Strategic initiatives
8.8.5 Bristol-Mayers Squibb Company
8.8.5.1 Company overview
8.8.5.2 Affymetrix
8.8.5.3 Company overview
8.8.5.4 Financial performance
8.8.5.5 Product benchmarking
8.8.5.6 Strategic initiatives
8.8.6 Takeda Pharmaceutical Company Limited
8.8.6.1 Company overview
8.8.6.2 Financial performance
8.8.6.3 Product benchmarking
8.8.6.4 Strategic initiatives
8.8.7 Teva Pharmaceutical Industries Ltd
8.8.7.1 Company overview
8.8.7.2 Financial performance
8.8.7.3 Product benchmarking
8.8.7.4 Strategic initiatives
8.8.8 F. Hoffmann-La Roche Ltd.
8.8.8.1 Company overview
8.8.8.2 Financial performance
8.8.8.3 Product benchmarking
8.8.8.4 Strategic initiatives
1.1 Market Segmentation
1.1.1 Segment scope
1.1.2 Regional scope
1.1.3 Estimates and Forecast Timeline
1.2 Research Methodology
1.3 Information Procurement
1.3.1 Purchased Database
1.3.2 GVR’s Internal Database
1.3.3 Secondary Sources
1.3.4 Primary Research
1.3.5 Details of Primary Research
1.4 Information or Data Analysis
1.4.1 Data Analysis Models
1.5 Market Formulation & Validation
1.6 Model Details
1.6.1 Commodity Flow Analysis
1.6.1.1 Approach 1: Commodity flow approach
1.6.1.2 Approach 2: Country wise market estimation using bottom up approach
1.6.1.3 Approach 3: Country wise market estimation using top down approach
1.7 Global Market: CAGR Calculation
1.8 Research Assumptions
1.9 Key KoL Responses
1.10 Market Share Calculations
1.11 List of Secondary Sources
1.12 Objectives
1.12.1 Objective 1:
1.12.2 Objective 2:
1.13 List of Abbreviations
CHAPTER 2 EXECUTIVE SUMMARY
2.1 Market Summary
CHAPTER 3 HEAD AND NECK CANCER THERAPEUTICS MARKET - INDUSTRY OUTLOOK
3.1 Market Lineage Outlook
3.1.1 Parent Market Lineage Outlook
3.1.2 Related/Ancillary Market Outlook
3.2 Penetration & Growth Prospect Mapping
3.3 Market Dynamics
3.3.1 Market Drivers Analysis
3.3.1.1 Increasing prevalence of head and neck cancers
3.3.1.2 Rising geriatric population
3.3.1.3 Increasing R&D and strong presence of pipeline product
3.3.1.4 Supportive reimbursment policies and rising awareness about disease
3.3.2 Market Restraint Analysis
3.3.2.1 Paucity of data related to safety and efficacy
3.3.2.2 High cost of treatments
3.4 Head and Neck Cancer Therapeutics Market Analysis Tools
3.4.2 Industry Analysis - Porter's
3.4.3 SWOT Analysis, By Factor (Political & Legal, Economic and Technological)
3.4.3.1 Political and Legal
3.4.3.2 Economic & Social
3.4.3.3 Technological
3.5 Reimbursement & Regulatory Scenario
3.5.1 North America
3.5.1 Europe
3.5.2 Asia Pacific
3.5.3 Latin America
3.5.4 MEA
3.6 Major Deals & Strategic Alliances
3.6.1 New Product Launch
3.6.2 Acquisition
3.6.3 Expansion
3.6.4 Partnerships
3.7 Pipeline analysis
CHAPTER 4 HEAD AND NECK CANCER THERAPEUTICS MARKET ANALYSIS: THERAPY TYPE SCOPE, 2018 - 2030 (REVENUE, USD MILLION)
4.1 Head and Neck Cancer Therapeutics Market: Therapy Type Movement Analysis
4.2 Chemotherapy
4.2.1 Chemotherapy market estimates and forecast, 2018 - 2030 (USD million)
4.3 Immunotherapy
4.3.1 Immunotherapy market estimates and forecast, 2018 - 2030 (USD million)
4.4 Targeted Therapy
4.4.1 Targeted therapy market estimates and forecast, 2018 - 2030 (USD million)
CHAPTER 5 HEAD AND NECK CANCER THERAPEUTICS MARKET ANALYSIS: ROUTE OF ADMINISTRATION SCOPE, 2018 - 2030 (REVENUE, USD MILLION)
5.1 Head and Neck Cancer Therapeutics Market: Route of Administration Movement Analysis
5.2 Injectables
5.2.1 Injectables market estimates and forecast, 2018 - 2030 (USD million)
5.3 Oral
5.3.1 Oral market estimates and forecast, 2018 - 2030 (USD million)
CHAPTER 6 HEAD AND NECK CANCER THERAPEUTICS MARKET ANALYSIS: DISTRIBUTION CHANNEL SCOPE, 2018 - 2030 (REVENUE, USD MILLION)
6.1 Head and Neck Cancer Therapeutics Market: Distribution Channel Movement Analysis
6.2 Retail & Specialty Pharmacies
6.2.1 Retail & specialty pharmacies market estimates and forecast, 2018 - 2030 (USD million)
6.3 Hospital Pharmacies
6.3.1 Hospital pharmacies market estimates and forecast, 2018 - 2030 (USD million)
6.4 Online Pharmacies
6.4.1 Online pharmacies market estimates and forecast, 2018 - 2030 (USD million)
CHAPTER 7 HEAD AND NECK CANCER THERAPEUTICS MARKET ANALYSIS, REGIONAL SCOPE, 2017-2030, (REVENUE, USD MILLION)
7.1 Market Share Analysis by Regional, 2021 & 2030
7.1.1 North America
7.1.1.1 North America market estimates and forecast, 2018 - 2030 (USD Million)
7.1.1.2 U.S.
7.1.1.2.1 U.S. market estimates and forecast, 2018 - 2030 (USD Million)
7.1.1.3 Canada
7.1.1.3.1 Canada market estimates and forecast, 2018 - 2030 (USD Million)
7.1.2 Europe
7.1.2.1 Europe market estimates and forecast, 2018 - 2030 (USD Million)
7.1.2.2 U.K.
7.1.2.2.1 U.K. market estimates and forecast, 2018 - 2030 (USD Million)
7.1.2.3 Germany
7.1.2.3.1 Germany market estimates and forecast, 2018 - 2030 (USD Million)
7.1.2.4 France
7.1.2.4.1 France market estimates and forecast, 2018 - 2030 (USD Million)
7.1.2.5 Italy
7.1.2.5.1 Italy market estimates and forecast, 2018 - 2030 (USD Million)
7.1.2.6 Spain
7.1.2.6.1 Spain market estimates and forecast, 2018 - 2030 (USD Million)
7.1.3 Asia Pacific
7.1.3.1 Asia Pacific market estimates and forecast, 2018 - 2030 (USD Million)
7.1.3.2 Japan
7.1.3.2.1 Japan market estimates and forecast, 2018 - 2030 (USD Million)
7.1.3.3 China
7.1.3.3.1 China market estimates and forecast, 2018 - 2030 (USD Million)
7.1.3.4 India
7.1.3.4.1 India market estimates and forecast, 2018 - 2030 (USD Million)
7.1.3.5 Australia
7.1.3.5.1 Australia market estimates and forecast, 2018 - 2030 (USD Million)
7.1.3.6 South Korea
7.1.3.6.1 South Korea market estimates and forecast, 2018 - 2030 (USD Million)
7.1.4 Latin America
7.1.4.1 Latin America market estimates and forecast, 2018 - 2030 (USD Million)
7.1.4.2 Brazil
7.1.4.2.1 Brazil market estimates and forecast, 2018 - 2030 (USD Million)
7.1.3.3 Mexico
7.1.3.3.1 Mexico market estimates and forecast, 2018 - 2030 (USD Million)
7.1.3.4 Argentina
7.1.3.4.1 Argentina market estimates and forecast, 2018 - 2030 (USD Million)
7.1.5 Middle East and Africa (MEA)
7.1.8.1 Middle East & Africa market estimates and forecast, 2018 - 2030 (USD Million)
7.1.8.2 South Africa
7.1.8.2.1 South Africa market estimates and forecast, 2018 - 2030 (USD Million)
7.1.3.3 Saudi Arabia
7.1.3.3.1 Saudi Arabia market estimates and forecast, 2018 - 2030 (USD Million)
7.1.3.4 South Africa
7.1.3.4.1 South Africa market estimates and forecast, 2018 - 2030 (USD Million)
CHAPTER 8 HEAD AND NECK CANCER THERAPEUTICS MARKET: COMPETITIVE ANALYSIS
8.1 Recent Developments and Impact Analysis, by Key Market Participants
8.1.1 Ansoff matrix`
8.2 Company Categorization
8.2.1 Innovators
8.2.2.1 Market Differentiators
8.3 Vendor Landscape
8.3.1 List of Key Distributors And Channel Partners
8.3.2 Key Customers
8.3.3 Key Company Market Share Analysis, 2020
8.4 Public Companies
8.4.1 Comapany Market Position analysis
8.4.2 Competitive dashboard analysis
8.5 Private Companies
8.5.1 List of Key Emerging Companies
8.6 Regional Network Map
8.8 Company Profiles
8.8.1 Eli Lilly and Company
8.8.1.1 Company overview
8.8.1.2 Financial performance
8.8.1.3 Product benchmarking
8.8.1.4 Strategic initiatives
8.8.2 Sanofi
8.8.2.1 Company overview
8.8.2.2 Financial performance
8.8.2.3 Product benchmarking
8.8.2.4 Strategic initiatives
8.8.3 Merck & Co., Inc.
8.8.3.1 Company overview
8.8.3.2 Financial performance
8.8.3.3 Product benchmarking
8.8.3.4 Strategic initiatives
8.8.4 Clingen Group plc.
8.8.4.1 Company overview
8.8.4.2 Financial performance
8.8.4.3 Product benchmarking
8.8.4.4 Strategic initiatives
8.8.5 Bristol-Mayers Squibb Company
8.8.5.1 Company overview
8.8.5.2 Affymetrix
8.8.5.3 Company overview
8.8.5.4 Financial performance
8.8.5.5 Product benchmarking
8.8.5.6 Strategic initiatives
8.8.6 Takeda Pharmaceutical Company Limited
8.8.6.1 Company overview
8.8.6.2 Financial performance
8.8.6.3 Product benchmarking
8.8.6.4 Strategic initiatives
8.8.7 Teva Pharmaceutical Industries Ltd
8.8.7.1 Company overview
8.8.7.2 Financial performance
8.8.7.3 Product benchmarking
8.8.7.4 Strategic initiatives
8.8.8 F. Hoffmann-La Roche Ltd.
8.8.8.1 Company overview
8.8.8.2 Financial performance
8.8.8.3 Product benchmarking
8.8.8.4 Strategic initiatives
LIST OF TABLES
TABLE 1 List of Secondary Sources
TABLE 2 List of Abbreviations
TABLE 3 Global Head and Neck Cancer Therapeutics Market, By Region, 2018 - 2030 (USD Million)
TABLE 4 Global Head and Neck Cancer Therapeutics Market, By Therapy Type, 2018 - 2030 (USD Million)
TABLE 5 Global Head and Neck Cancer Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
TABLE 6 Global Head and Neck Cancer Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
TABLE 7 North America Head and Neck Cancer Therapeutics Market, By Therapy Type, 2018 - 2030 (USD Million)
TABLE 8 North America Head and Neck Cancer Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
TABLE 9 North America Head and Neck Cancer Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
TABLE 10 U.S. Head and Neck Cancer Therapeutics Market, By Therapy Type, 2018 - 2030 (USD Million)
TABLE 11 U.S. Head and Neck Cancer Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
TABLE 12 U.S. Head and Neck Cancer Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
TABLE 13 Canada Head and Neck Cancer Therapeutics Market, By Therapy Type, 2018 - 2030 (USD Million)
TABLE 14 Canada Head and Neck Cancer Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
TABLE 15 Canada Head and Neck Cancer Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
TABLE 16 Europe Head and Neck Cancer Therapeutics Market, By Therapy Type, 2018 - 2030 (USD Million)
TABLE 17 Europe Head and Neck Cancer Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
TABLE 18 Europe Head and Neck Cancer Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
TABLE 19 Germany Head and Neck Cancer Therapeutics Market, By Therapy Type, 2018 - 2030 (USD Million)
TABLE 20 Germany Head and Neck Cancer Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
TABLE 21 Germany Head and Neck Cancer Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
TABLE 22 U.K. Head and Neck Cancer Therapeutics Market, By Therapy Type, 2018 - 2030 (USD Million)
TABLE 23 U.K. Head and Neck Cancer Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
TABLE 24 U.K. Head and Neck Cancer Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
TABLE 25 France Head and Neck Cancer Therapeutics Market, By Therapy Type, 2018 - 2030 (USD Million)
TABLE 26 France Head and Neck Cancer Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
TABLE 27 France Head and Neck Cancer Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
TABLE 28 Italy Head and Neck Cancer Therapeutics Market, By Therapy Type, 2018 - 2030 (USD Million)
TABLE 29 Italy Head and Neck Cancer Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
TABLE 30 Italy Head and Neck Cancer Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
TABLE 31 Spain Head and Neck Cancer Therapeutics Market, By Therapy Type, 2018 - 2030 (USD Million)
TABLE 32 Spain Head and Neck Cancer Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
TABLE 33 Spain Head and Neck Cancer Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
TABLE 34 Asia Pacific Head and Neck Cancer Therapeutics Market, By Therapy Type, 2018 - 2030 (USD Million)
TABLE 35 Asia Pacific Head and Neck Cancer Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
TABLE 36 Asia Pacific Head and Neck Cancer Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
TABLE 37 Japan Head and Neck Cancer Therapeutics Market, By Therapy Type, 2018 - 2030 (USD Million)
TABLE 38 Japan Head and Neck Cancer Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
TABLE 39 Japan Head and Neck Cancer Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
TABLE 40 China Head and Neck Cancer Therapeutics Market, By Therapy Type, 2018 - 2030 (USD Million)
TABLE 41 China Head and Neck Cancer Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
TABLE 42 China Head and Neck Cancer Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
TABLE 43 India Head and Neck Cancer Therapeutics Market, By Therapy Type, 2018 - 2030 (USD Million)
TABLE 44 India Head and Neck Cancer Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
TABLE 45 India Head and Neck Cancer Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
TABLE 46 South Korea Head and Neck Cancer Therapeutics Market, By Therapy Type, 2018 - 2030 (USD Million)
TABLE 47 South Korea Head and Neck Cancer Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
TABLE 48 South Korea Head and Neck Cancer Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
TABLE 49 Australia Head and Neck Cancer Therapeutics Market, By Therapy Type, 2018 - 2030 (USD Million)
TABLE 50 Australia Head and Neck Cancer Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
TABLE 51 Austalia Head and Neck Cancer Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
TABLE 52 Latin America Head and Neck Cancer Therapeutics Market, By Therapy Type, 2018 - 2030 (USD Million)
TABLE 53 Latin America Head and Neck Cancer Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
TABLE 54 Latin America Head and Neck Cancer Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
TABLE 55 Brazil Head and Neck Cancer Therapeutics Market, By Therapy Type, 2018 - 2030 (USD Million)
TABLE 56 Brazil Head and Neck Cancer Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
TABLE 57 Brazil Head and Neck Cancer Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
TABLE 58 Mexico Head and Neck Cancer Therapeutics Market, By Therapy Type, 2018 - 2030 (USD Million)
TABLE 59 Mexico Head and Neck Cancer Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
TABLE 60 Mexico Head and Neck Cancer Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
TABLE 61 Argentina Head and Neck Cancer Therapeutics Market, By Therapy Type, 2018 - 2030 (USD Million)
TABLE 62 Argentina Head and Neck Cancer Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
TABLE 63 Argentina Head and Neck Cancer Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
TABLE 64 Middle East & Africa Head and Neck Cancer Therapeutics Market, By Therapy Type, 2018 - 2030 (USD Million)
TABLE 65 Middle East & Africa Head and Neck Cancer Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
TABLE 66 Middle East & Africa Head and Neck Cancer Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
TABLE 67 Saudi Arabia Head and Neck Cancer Therapeutics Market, By Therapy Type, 2018 - 2030 (USD Million)
TABLE 68 Saudi Arabia Head and Neck Cancer Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
TABLE 69 Saudi Arabia Head and Neck Cancer Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
TABLE 70 South Africa Head and Neck Cancer Therapeutics Market, By Therapy Type, 2018 - 2030 (USD Million)
TABLE 71 South Africa Head and Neck Cancer Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
TABLE 72 South Africa Head and Neck Cancer Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
TABLE 73 UAE Head and Neck Cancer Therapeutics Market, By Therapy Type, 2018 - 2030 (USD Million)
TABLE 74 UAE Head and Neck Cancer Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
TABLE 75 UAE Head and Neck Cancer Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
TABLE 1 List of Secondary Sources
TABLE 2 List of Abbreviations
TABLE 3 Global Head and Neck Cancer Therapeutics Market, By Region, 2018 - 2030 (USD Million)
TABLE 4 Global Head and Neck Cancer Therapeutics Market, By Therapy Type, 2018 - 2030 (USD Million)
TABLE 5 Global Head and Neck Cancer Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
TABLE 6 Global Head and Neck Cancer Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
TABLE 7 North America Head and Neck Cancer Therapeutics Market, By Therapy Type, 2018 - 2030 (USD Million)
TABLE 8 North America Head and Neck Cancer Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
TABLE 9 North America Head and Neck Cancer Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
TABLE 10 U.S. Head and Neck Cancer Therapeutics Market, By Therapy Type, 2018 - 2030 (USD Million)
TABLE 11 U.S. Head and Neck Cancer Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
TABLE 12 U.S. Head and Neck Cancer Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
TABLE 13 Canada Head and Neck Cancer Therapeutics Market, By Therapy Type, 2018 - 2030 (USD Million)
TABLE 14 Canada Head and Neck Cancer Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
TABLE 15 Canada Head and Neck Cancer Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
TABLE 16 Europe Head and Neck Cancer Therapeutics Market, By Therapy Type, 2018 - 2030 (USD Million)
TABLE 17 Europe Head and Neck Cancer Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
TABLE 18 Europe Head and Neck Cancer Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
TABLE 19 Germany Head and Neck Cancer Therapeutics Market, By Therapy Type, 2018 - 2030 (USD Million)
TABLE 20 Germany Head and Neck Cancer Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
TABLE 21 Germany Head and Neck Cancer Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
TABLE 22 U.K. Head and Neck Cancer Therapeutics Market, By Therapy Type, 2018 - 2030 (USD Million)
TABLE 23 U.K. Head and Neck Cancer Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
TABLE 24 U.K. Head and Neck Cancer Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
TABLE 25 France Head and Neck Cancer Therapeutics Market, By Therapy Type, 2018 - 2030 (USD Million)
TABLE 26 France Head and Neck Cancer Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
TABLE 27 France Head and Neck Cancer Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
TABLE 28 Italy Head and Neck Cancer Therapeutics Market, By Therapy Type, 2018 - 2030 (USD Million)
TABLE 29 Italy Head and Neck Cancer Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
TABLE 30 Italy Head and Neck Cancer Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
TABLE 31 Spain Head and Neck Cancer Therapeutics Market, By Therapy Type, 2018 - 2030 (USD Million)
TABLE 32 Spain Head and Neck Cancer Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
TABLE 33 Spain Head and Neck Cancer Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
TABLE 34 Asia Pacific Head and Neck Cancer Therapeutics Market, By Therapy Type, 2018 - 2030 (USD Million)
TABLE 35 Asia Pacific Head and Neck Cancer Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
TABLE 36 Asia Pacific Head and Neck Cancer Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
TABLE 37 Japan Head and Neck Cancer Therapeutics Market, By Therapy Type, 2018 - 2030 (USD Million)
TABLE 38 Japan Head and Neck Cancer Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
TABLE 39 Japan Head and Neck Cancer Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
TABLE 40 China Head and Neck Cancer Therapeutics Market, By Therapy Type, 2018 - 2030 (USD Million)
TABLE 41 China Head and Neck Cancer Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
TABLE 42 China Head and Neck Cancer Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
TABLE 43 India Head and Neck Cancer Therapeutics Market, By Therapy Type, 2018 - 2030 (USD Million)
TABLE 44 India Head and Neck Cancer Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
TABLE 45 India Head and Neck Cancer Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
TABLE 46 South Korea Head and Neck Cancer Therapeutics Market, By Therapy Type, 2018 - 2030 (USD Million)
TABLE 47 South Korea Head and Neck Cancer Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
TABLE 48 South Korea Head and Neck Cancer Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
TABLE 49 Australia Head and Neck Cancer Therapeutics Market, By Therapy Type, 2018 - 2030 (USD Million)
TABLE 50 Australia Head and Neck Cancer Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
TABLE 51 Austalia Head and Neck Cancer Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
TABLE 52 Latin America Head and Neck Cancer Therapeutics Market, By Therapy Type, 2018 - 2030 (USD Million)
TABLE 53 Latin America Head and Neck Cancer Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
TABLE 54 Latin America Head and Neck Cancer Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
TABLE 55 Brazil Head and Neck Cancer Therapeutics Market, By Therapy Type, 2018 - 2030 (USD Million)
TABLE 56 Brazil Head and Neck Cancer Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
TABLE 57 Brazil Head and Neck Cancer Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
TABLE 58 Mexico Head and Neck Cancer Therapeutics Market, By Therapy Type, 2018 - 2030 (USD Million)
TABLE 59 Mexico Head and Neck Cancer Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
TABLE 60 Mexico Head and Neck Cancer Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
TABLE 61 Argentina Head and Neck Cancer Therapeutics Market, By Therapy Type, 2018 - 2030 (USD Million)
TABLE 62 Argentina Head and Neck Cancer Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
TABLE 63 Argentina Head and Neck Cancer Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
TABLE 64 Middle East & Africa Head and Neck Cancer Therapeutics Market, By Therapy Type, 2018 - 2030 (USD Million)
TABLE 65 Middle East & Africa Head and Neck Cancer Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
TABLE 66 Middle East & Africa Head and Neck Cancer Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
TABLE 67 Saudi Arabia Head and Neck Cancer Therapeutics Market, By Therapy Type, 2018 - 2030 (USD Million)
TABLE 68 Saudi Arabia Head and Neck Cancer Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
TABLE 69 Saudi Arabia Head and Neck Cancer Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
TABLE 70 South Africa Head and Neck Cancer Therapeutics Market, By Therapy Type, 2018 - 2030 (USD Million)
TABLE 71 South Africa Head and Neck Cancer Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
TABLE 72 South Africa Head and Neck Cancer Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
TABLE 73 UAE Head and Neck Cancer Therapeutics Market, By Therapy Type, 2018 - 2030 (USD Million)
TABLE 74 UAE Head and Neck Cancer Therapeutics Market, By Route of Administration, 2018 - 2030 (USD Million)
TABLE 75 UAE Head and Neck Cancer Therapeutics Market, By Distribution Channel, 2018 - 2030 (USD Million)
LIST OF FIGURES
FIG. 1 Head and neck cancer therapeutics market segmentation
FIG. 2 Market research process
FIG. 3 Data triangulation techniques
FIG. 4 Primary research pattern
FIG. 5 Market research approaches
FIG. 6 Value-chain-based sizing & forecasting
FIG. 7 QFD modelling for market share assessment
FIG. 8 Market formulation & validation
FIG. 9 Head and neck cancer therapeutics market snapshot
FIG. 10 Parent market outlook
FIG. 11 Related/ancillary market outlook, revenue, 2021, (USD Million)
FIG. 12 Penetration and growth prospect mapping
FIG. 13 Head and neck cancer therapeutics market driver impact
FIG. 14 Head and neck cancer therapeutics market restraint impact
FIG. 15 SWOT analysis, by factor (political & legal, economic, and technological)
FIG. 16 Industry Analysis - Porter’s
FIG. 17 Strategy mapping
FIG. 18 Head and neck cancer therapeutics market: Therapy type outlook and key takeaways
FIG. 19 Head and neck cancer therapeutics market: Therapy type movement analysis & market share 2021 & 2030
FIG. 20 Chemotherapy market estimates and forecast, 2018 - 2030 (USD Million)
FIG. 21 Immunotherapy market estimates and forecast, 2018 - 2030 (USD Million)
FIG. 22 Targeted therapy market estimates and forecast, 2018 - 2030 (USD Million)
FIG. 23 Head and neck cancer therapeutics market: Route of Administration outlook and key takeaways
FIG. 24 Head and neck cancer therapeutics market: Route of administration movement analysis & market share 2021 & 2030
FIG. 25 Injectable market estimates and forecast, 2018 - 2030 (USD Million)
FIG. 26 Oral market estimates and forecast, 2018 - 2030 (USD Million)
FIG. 27 Head and neck cancer therapeutics market: Distribution Channel outlook and key takeaways
FIG. 28 Head and neck cancer therapeutics market: Distribution Channel movement analysis & market share 2021 & 2030
FIG. 29 Retail & specialty pharmacies market estimates and forecast, 2018 - 2030 (USD Million)
FIG. 30 Hospital pharmacies market estimates and forecast, 2018 - 2030 (USD Million)
FIG. 31 Online pharmacies market estimates and forecast, 2018 - 2030 (USD Million)
FIG. 32 Head and neck cancer therapeutics: Regional outlook and key takeaways
FIG. 33 Regional outlook, 2021 & 2030
FIG. 34 North America
FIG. 35 North America market estimates and forecast, 2018 - 2030 (USD Million)
FIG. 36 U.S.
FIG. 37 U.S. market estimates and forecast, 2018 - 2030 (USD Million)
FIG. 38 Canada
FIG. 39 Canada market estimates and forecast, 2018 - 2030 (USD Million)
FIG. 40 Europe
FIG. 41 Europe market estimates and forecast, 2018 - 2030 (USD Million)
FIG. 42 U.K.
FIG. 43 U.K. market estimates and forecast, 2018 - 2030 (USD Million)
FIG. 44 Germany
FIG. 45 Germany market estimates and forecast, 2018 - 2030 (USD Million)
FIG. 46 France
FIG. 47 France market estimates and forecast, 2018 - 2030 (USD Million)
FIG. 48 Italy
FIG. 49 Italy market estimates and forecast, 2018 - 2030 (USD Million)
FIG. 50 Spain
FIG. 51 Spain market estimates and forecast, 2018 - 2030 (USD Million)
FIG. 52 Asia Pacific
FIG. 53 Asia Pacific market estimates and forecast, 2018 - 2030 (USD Million)
FIG. 54 Japan
FIG. 55 Japan market estimates and forecast, 2018 - 2030(USD Million)
FIG. 56 China
FIG. 57 China market estimates and forecast, 2018 - 2030 (USD Million)
FIG. 58 India
FIG. 59 India market estimates and forecast, 2018 - 2030 (USD Million)
FIG. 60 South Korea
FIG. 61 South Korea market estimates and forecast, 2018 - 2030 (USD Million)
FIG. 62 Australia
FIG. 63 Australia market estimates and forecast, 2018 - 2030 (USD Million)
FIG. 64 Latin America
FIG. 65 Latin America market estimates and forecast, 2018 - 2030 (USD Million)
FIG. 66 Brazil
FIG. 67 Brazil market estimates and forecast, 2018 - 2030 (USD Million)
FIG. 68 Mexico
FIG. 69 Mexico market estimates and forecast, 2018 - 2030 (USD Million)
FIG. 70 Argentina
FIG. 71 Argentina market estimates and forecast, 2018 - 2030 (USD Million)
FIG. 72 Middle East & Africa
FIG. 73 MEA market estimates and forecast, 2018 - 2030 (USD Million)
FIG. 74 South Africa
FIG. 75 South Africa market estimates and forecast, 2018 - 2030 (USD Million)
FIG. 76 Saudi Arabia
FIG. 77 Saudi Arabia market estimates and forecast, 2018 - 2030 (USD Million)
FIG. 78 UAE
FIG. 79 UAE market estimates and forecast, 2018 - 2030 (USD Million)
FIG. 80 Market differentiators
FIG. 81 Key company market share analysis, 2021
FIG. 82 Company market position analysis
FIG. 83 Competitive dashboard analysis
FIG. 84 Regional network map
FIG. 1 Head and neck cancer therapeutics market segmentation
FIG. 2 Market research process
FIG. 3 Data triangulation techniques
FIG. 4 Primary research pattern
FIG. 5 Market research approaches
FIG. 6 Value-chain-based sizing & forecasting
FIG. 7 QFD modelling for market share assessment
FIG. 8 Market formulation & validation
FIG. 9 Head and neck cancer therapeutics market snapshot
FIG. 10 Parent market outlook
FIG. 11 Related/ancillary market outlook, revenue, 2021, (USD Million)
FIG. 12 Penetration and growth prospect mapping
FIG. 13 Head and neck cancer therapeutics market driver impact
FIG. 14 Head and neck cancer therapeutics market restraint impact
FIG. 15 SWOT analysis, by factor (political & legal, economic, and technological)
FIG. 16 Industry Analysis - Porter’s
FIG. 17 Strategy mapping
FIG. 18 Head and neck cancer therapeutics market: Therapy type outlook and key takeaways
FIG. 19 Head and neck cancer therapeutics market: Therapy type movement analysis & market share 2021 & 2030
FIG. 20 Chemotherapy market estimates and forecast, 2018 - 2030 (USD Million)
FIG. 21 Immunotherapy market estimates and forecast, 2018 - 2030 (USD Million)
FIG. 22 Targeted therapy market estimates and forecast, 2018 - 2030 (USD Million)
FIG. 23 Head and neck cancer therapeutics market: Route of Administration outlook and key takeaways
FIG. 24 Head and neck cancer therapeutics market: Route of administration movement analysis & market share 2021 & 2030
FIG. 25 Injectable market estimates and forecast, 2018 - 2030 (USD Million)
FIG. 26 Oral market estimates and forecast, 2018 - 2030 (USD Million)
FIG. 27 Head and neck cancer therapeutics market: Distribution Channel outlook and key takeaways
FIG. 28 Head and neck cancer therapeutics market: Distribution Channel movement analysis & market share 2021 & 2030
FIG. 29 Retail & specialty pharmacies market estimates and forecast, 2018 - 2030 (USD Million)
FIG. 30 Hospital pharmacies market estimates and forecast, 2018 - 2030 (USD Million)
FIG. 31 Online pharmacies market estimates and forecast, 2018 - 2030 (USD Million)
FIG. 32 Head and neck cancer therapeutics: Regional outlook and key takeaways
FIG. 33 Regional outlook, 2021 & 2030
FIG. 34 North America
FIG. 35 North America market estimates and forecast, 2018 - 2030 (USD Million)
FIG. 36 U.S.
FIG. 37 U.S. market estimates and forecast, 2018 - 2030 (USD Million)
FIG. 38 Canada
FIG. 39 Canada market estimates and forecast, 2018 - 2030 (USD Million)
FIG. 40 Europe
FIG. 41 Europe market estimates and forecast, 2018 - 2030 (USD Million)
FIG. 42 U.K.
FIG. 43 U.K. market estimates and forecast, 2018 - 2030 (USD Million)
FIG. 44 Germany
FIG. 45 Germany market estimates and forecast, 2018 - 2030 (USD Million)
FIG. 46 France
FIG. 47 France market estimates and forecast, 2018 - 2030 (USD Million)
FIG. 48 Italy
FIG. 49 Italy market estimates and forecast, 2018 - 2030 (USD Million)
FIG. 50 Spain
FIG. 51 Spain market estimates and forecast, 2018 - 2030 (USD Million)
FIG. 52 Asia Pacific
FIG. 53 Asia Pacific market estimates and forecast, 2018 - 2030 (USD Million)
FIG. 54 Japan
FIG. 55 Japan market estimates and forecast, 2018 - 2030(USD Million)
FIG. 56 China
FIG. 57 China market estimates and forecast, 2018 - 2030 (USD Million)
FIG. 58 India
FIG. 59 India market estimates and forecast, 2018 - 2030 (USD Million)
FIG. 60 South Korea
FIG. 61 South Korea market estimates and forecast, 2018 - 2030 (USD Million)
FIG. 62 Australia
FIG. 63 Australia market estimates and forecast, 2018 - 2030 (USD Million)
FIG. 64 Latin America
FIG. 65 Latin America market estimates and forecast, 2018 - 2030 (USD Million)
FIG. 66 Brazil
FIG. 67 Brazil market estimates and forecast, 2018 - 2030 (USD Million)
FIG. 68 Mexico
FIG. 69 Mexico market estimates and forecast, 2018 - 2030 (USD Million)
FIG. 70 Argentina
FIG. 71 Argentina market estimates and forecast, 2018 - 2030 (USD Million)
FIG. 72 Middle East & Africa
FIG. 73 MEA market estimates and forecast, 2018 - 2030 (USD Million)
FIG. 74 South Africa
FIG. 75 South Africa market estimates and forecast, 2018 - 2030 (USD Million)
FIG. 76 Saudi Arabia
FIG. 77 Saudi Arabia market estimates and forecast, 2018 - 2030 (USD Million)
FIG. 78 UAE
FIG. 79 UAE market estimates and forecast, 2018 - 2030 (USD Million)
FIG. 80 Market differentiators
FIG. 81 Key company market share analysis, 2021
FIG. 82 Company market position analysis
FIG. 83 Competitive dashboard analysis
FIG. 84 Regional network map
